The ethical debate around neonatal WGS screening is yet to be resolved but its negative aspects seem outweighed by the prospective benefits that hold the potential to save lives through early diagnosis and personalized medicine. Currently, screening for many prevalent oncogenic genes for example, BRCA 1 and BRCA 2, are not done unless the disease holds a place in family history. If WGS was incorporated into neonatal screening, such genes would be identified at a very early age which can then allow patients to take preventive measures and undergo routine checkups throughout their lives so that the most fitting treatment according to their genetic makeup can be provided if they happen to develop the disease. Therefore, although the technology
